Assessing diagnosis and managing respiratory and cardiac complications of sarcoglycanopathy

References

• Wicklund MP. The limb-girdle muscular dystrophies. Continuum (Minneapolis, Minn.). 2019;25(6):1599–1618.
   PubMedGoogle Scholar
• Angelini C, Fanin M, Freda MP, et al., The clinical spectrum of sarcoglycanopathies. Neurology. 52(1): 176–179. 1999.
   PubMed Web of Science ®Google Scholar
• Kirschner J, Lochmller H. Sarcoglycanopathies. Hand Clin Neurol. 2011;101:41–46.
   PubMedGoogle Scholar
• Angelini C, Fanin M. Pathogenesis, clinical features and diagnosis of sarcoglycanopathies. Expert Opinion on Orphan Drugs. 2016;4(12):1239–1251.
   Web of Science ®Google Scholar
• Bushby KM, Beckmann JS. 30th and 31st ENMC international workshops, Naarden, The Netherlands, Held 6–8 January 1995. Neuromuscul Disord. 1995;5(4):337–343.
   PubMed Web of Science ®Google Scholar
• Straub V, Murphy A, Udd B. 229th ENMC international workshop: limb girdle muscular dystrophies – nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. Neuromuscul Disord. 2018;28(8):702–710.
   PubMed Web of Science ®Google Scholar
• Fanin M, Nascimbeni AC, Aurino S, et al., Frequency of LGMD gene mutations in italian patients with distinct clinical phenotypes. Neurology. 72(16): 1432–1435. 2009.
   PubMed Web of Science ®Google Scholar
• Fanin M, Duggan DJ, Mostacciuolo ML, et al. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet. 1997;34(12):973–977.
   PubMed Web of Science ®Google Scholar
• Norwood FLM, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132(11):3175–3176.
   PubMed Web of Science ®Google Scholar
• Ozawa E, Noguchi S, Mizuno Y, et al. From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy. Muscle Nerve. 1998;21(4):421–487.
   PubMed Web of Science ®Google Scholar
• Anderson LVB, Davison K. Multiplex western blotting for the analysis of muscular dystrophy proteins. Am J Pathol. 1999;154(4):1017–1022.
   PubMed Web of Science ®Google Scholar
• Klinge L, Dekomien G, Aboumousa A, et al. Sarcoglycanopathies: can muscle immuno-analysis predict the genotype? Neuromusc Disord. 2008;18(12):934–941.
   PubMed Web of Science ®Google Scholar
• Fanin M, Nascimbeni AC, Angelini C. Muscle protein analysis in the detection of heterozygotes for recessive limb girdle muscular dystrophy type 2B and 2E. Neuromusc Disord. 2006;16(11):792–799.
   PubMed Web of Science ®Google Scholar
• Giugliano T, Fanin M, Savarese M, et al. Identification of an intragenic deletion in the SGCB gene through a re-evaluation of negative next generation sequencing results. Neuromusc Disord. 2016;26(6):367–369.
   PubMed Web of Science ®Google Scholar
• Nigro V, Aurino S, Piluso G. Limb girdle muscular dystrophies: update on genetic diagnosis and therapeutic approaches. Curr Opin Neurol. 2011;24(5):429–436.
   PubMed Web of Science ®Google Scholar
• Alonso-Pérez J, González-Quereda L, Bello L, et al., New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain. 143(9): 2696–2708. 2020. .
   PubMedGoogle Scholar
• Politano L, Nigro V, Passamano L, et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromusc Disord. 2001;11:178–185.
   PubMed Web of Science ®Google Scholar
• Trucco F, Pedemonte M, Fiorillo C, et al. Detection of early nocturnal hypoventilation in neuromuscular disorders. J Int Med Res. 2018;46(3):1153–1161.
   PubMed Web of Science ®Google Scholar
• Barresi R, et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet. 2000;37(2):102–107.
   PubMed Web of Science ®Google Scholar
• Fanin M, Melacini P, Boito C, et al. LGMD2E patients risk developing dilated cardiomyopathy. Neuromusc Disord. 2003;13(4):303–309.
   PubMed Web of Science ®Google Scholar
• Calvo F, Teijeira S, Fernandez JM, et al. Evaluation of heart involvement in γ-sarcoglycanopathy (LGMD2C).A study of ten patients. Neuromusc Disord. 2000;10(8):560–566.
   PubMed Web of Science ®Google Scholar
• Fayssoil A, Ogna A, Chaffaut C, et al. Natural history of cardiac and respiratory involvement, prognosis and predictive factors for long-term survival in adult patients with Limb Girdle muscular dystrophies type 2C and 2D. PLos One. 2016;11(4):e0153095.
   PubMed Web of Science ®Google Scholar
• Melacini P, Fanin M, Duggan DJ, et al., Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve. 22(4): 473–479. 1999. .
   PubMed Web of Science ®Google Scholar
• Meznaric-Petrusa M, Kralj E, Angelini C, et al. Cardiomyopathy in a patient with limb-girdle muscular dystrophy type 2D: pathomorphological aspects. Forens Sci Intl Suppl Series. 2009;1:58–62.
   Google Scholar
• Alavi A, Esmaeili S, Nilipour Y, et al. LGMD2E is the most common type of sarcoglycanopathies in the Iranian population. J Neurogenet. 2017;31(3):161–169.
   PubMed Web of Science ®Google Scholar
• Semplicini C, Vissing J, Dahlqvist JR, et al. Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology. 2015;84(17):1772–1781.
   PubMed Web of Science ®Google Scholar
• Angelini C, Tasca E, Nascimbeni AC, et al. Muscle fatigue, nNOS and muscle fiber atrophy in limb girdle muscular dystrophy. Acta Myol. 2014;33(3):119–126.
   PubMedGoogle Scholar
• Benditt JO. Respiratory care of patients with neuromuscular disease. Respir Care. 2019;64(6):679–688.
   PubMedGoogle Scholar
• Angelini C, Fanin M, Menegazzo E, et al., Homozygous α-sarcoglycan mutation in two siblings: one asymptomatic and one steroid-responsive mild limb-girdle muscular dystrophy patients. Muscle Nerve. 21(6): 769–775. 1998. .
   PubMed Web of Science ®Google Scholar
• Wong-Kisiel LC, Kuntz NL. Two siblings with limb-girdle muscular dystrophy type 2E responsive to deflazacort. Neuromusc disord 2010;20:122-4Connolly AM, Pestronk A, Mehta S, Al-Lozi M. Primary α-sarcoglycan deficiency responsive to immunosuppression over three years. Muscle Nerve. 1998;21:(11):1549–1553.
   PubMedGoogle Scholar
• Connolly AM, Pestronk A, Mehta S, et al. α-sarcoglycan deficiency responsive to immunosuppression over three years. Muscle Nerve. 1998;21(11):1549–1553.
   PubMed Web of Science ®Google Scholar
• Albuquerque MAV, Abath-Neto O, Maximino JR, et al. Clinical aspects of patients with sarcoglycanopathies under steroid therapy. Arq Neuropsiquiatr. 2014;72(10):768–772.
   PubMed Web of Science ®Google Scholar
• Bauer R, Blain A, Greally E, et al. Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. Neuromuscul Disord. 2010;20(1):21–28.
   PubMed Web of Science ®Google Scholar
• Soheili T, Gicquel E, Poupiot J, et al. Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications. Hum Mut. 2011;33(2):429–439.
   PubMed Web of Science ®Google Scholar
• Bartoli M, Gicquel E, Barrault L, et al. Mannosidase I inhibition rescues the human α-sarcoglycan R77C recurrent mutation. Human Molecular Genetics. 2008;17(9):1214–1221.
   PubMed Web of Science ®Google Scholar
• Gastaldello S, D’Angelo S, Franzoso S, et al. Inhibition of proteasome activity promotes the correct localization of disease-causing α-sarcoglycan mutants in HEK-293 cells constitutively expressing β-, γ-, and δ-Sarcoglycan. Am J Pathol. 2008;173(1):170–181.
   PubMed Web of Science ®Google Scholar
• Bianchini E, Fanin M, Mamchaoui K, et al. Unveiling the degradative route of the V247M α-sarcoglycan mutant responsible for LGMD-2D. Human Molecular Genetics. 2014;23(14):3746–3758.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Gu Y, Iwanaga Y, et al. Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer. Circulation. 2002;105(4):502–508.
   PubMed Web of Science ®Google Scholar
• https://investorrelations.sarepta.com/news-releases/news-releasedetails/sarepta-therapeutics-investigational-gene-therapy-srp-9003
   Google Scholar
• Van der Kooi AJ, Frankhuizen WS, Barth PG, et al. Limb-girdle muscular dystrophy in the Netherlands: gene defect identified in half the families. Neurology. 2007;68(24):2125–2128.
   PubMed Web of Science ®Google Scholar
• Vainzof M, Passos-Bueno MR, Pavanello RCM, et al. Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population. J Neurol Sci. 1999;164(1):44–49.
   PubMed Web of Science ®Google Scholar
• Guimarães‐Costa R, Fernández‐Eulate G, Wahbi K, et al. Clinical correlations and long-term follow-up in 100 patients with sarcoglycanopathies. Eur J Neurol. 2020. doi:10.1111/ene.14592.
   PubMedGoogle Scholar
• Tasca G, Monforte M, Díaz-Manera J, et al., MRI in sarcoglycanopathies: a large international cohort study. J Neurol Neurosurg Psychiatry. 89(1): 72–77. 2018. .
   PubMed Web of Science ®Google Scholar
• Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores α-sarcoglycan and associated proteins. Ann Neurol. 2009;66(3):290–297.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Rodino-Klapac LR, Rosales XQ, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol. 2010;68(5):629–638.
   PubMed Web of Science ®Google Scholar